Zelnorm Chronic Constipation Claim Could Increase Target Market By 50%
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis’ upcoming sNDA for a Zelnorm chronic constipation indication could increase the potential patient population for the drug by roughly 50%.